Anders Månsson at DNB Carnegie Småbolagsdag

Iconovo’s new Interim CEO, Anders Månsson, made his first official appearance for the company when he presented Iconovo at DNB Carnegie’s Småbolagsdag on 27 November. The presentation marked an important introduction of Anders in his new role at Iconovo.

To watch the presentation, please follow the link.

LinkedIn
Email

Related

Iconovo’s CEO interviewed by DNB Carnegie

Iconovo’s CEO Anders Månsson, was recently interviewed by DNB Carnegie to discuss the company’s latest quarterly report.
Read more

Iconovo carries out a directed issue of shares of approx. SEK 25 million and a rights issue of shares of approx. SEK 24.6 million

The Board of Directors of Iconovo AB (“Iconovo” or the “Company”) has today resolved on a directed share issue of approximately SEK 25 million (the “Directed Issue”), and on an issue of shares of approximately SEK 24.6 million with preferential rights for the Company’s existing shareholders (the “Rights Issue”, together the “Issues”).
Read more

Iconovo appoints Anders Månsson as new CEO

Iconovo AB (publ), a leader in the development of inhalable drugs based on proprietary inhalers and dry powder formulations, has today appointed Anders Månsson as interim CEO of Iconovo AB. The Board of Directors has in parallel initiated a process to recruit a permanent CEO, for which Anders also is a candidate.
Read more